VTE risk assessment in cancer. Who needs prophylaxis and who does not?

Hämostaseologie
Cihan Ay, Ingrid Pabinger

Abstract

Venous thromboembolism (VTE) in patients with cancer is associated with an increased morbidity and mortality, and its prevention is of major clinical importance. However, the VTE rates in the cancer population vary between 0.5% - 20%, depending on cancer-, treatment- and patient-related factors. The most important contributors to VTE risk are the tumor entity, stage and certain anti-cancer treatments. Cancer surgery represents a strong risk factor for VTE, and medical oncology patients are at increased risk of developing VTE, especially when receiving chemotherapy or immunomodulatory drugs. Also biomarkers have been investigated for their usefulness to predict risk of VTE (e.g. elevated leukocyte and platelet counts, soluble P-selectin, D-dimer, etc.). In order to identify cancer patients at high risk of VTE and to improve risk stratification, risk assessment models have been developed, which contain both clinical parameters and biomarkers. While primary thromboprophylaxis with low-molecular-weight-heparin (LMWH) is recommended postoperatively for a period of up to 4 weeks after major cancer surgery, the evidence is less clear for medical oncology patients. Thromboprophylaxis in hospitalized medical oncology patients is advocat...Continue Reading

References

Mar 29, 2002·The New England Journal of Medicine·David BergqvistUNKNOWN ENOXACAN II Investigators
Jun 1, 2002·Archives of Internal Medicine·John A HeitL Joseph Melton
Sep 30, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M E T TesselaarS Osanto
Feb 11, 2005·JAMA : the Journal of the American Medical Association·Jeanet W BlomFrits R Rosendaal
Nov 12, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K KrögerM E Scheulen
Dec 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vincent RajkumarUNKNOWN Eastern Cooperative Oncology Group
Jan 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alok A KhoranaGary H Lyman
Jan 25, 2006·The American Journal of Medicine·Paul D SteinRonald E Olson
Feb 8, 2006·Journal of Thrombosis and Haemostasis : JTH·J W BlomF R Rosendaal
Mar 1, 2006·Archives of Internal Medicine·Helen K ChewRichard H White
Jul 25, 2007·Archives of Internal Medicine·Frederick A SpencerRobert J Goldberg
Aug 10, 2007·Journal of the National Cancer Institute·Frank A ScappaticciHerbert Hurwitz
Mar 17, 2009·Best Practice & Research. Clinical Haematology·Ted Wun, Richard H White
Jul 10, 2009·The Cochrane Database of Systematic Reviews·Julia BohliusAndreas Engert
Jul 29, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cihan AyIngrid Pabinger
Sep 26, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·R VormittagI Pabinger
May 15, 2010·Thrombosis Research·Cihan Ay, Ingrid Pabinger
Sep 11, 2010·Blood·Cihan AyIngrid Pabinger
Sep 30, 2010·Journal of Thrombosis and Haemostasis : JTH·R KanzI Pabinger
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboMario Boccadoro
Apr 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cihan AyIngrid Pabinger
Aug 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Russell A MooreHani Hassoun
Oct 6, 2011·Hämostaseologie·A Falanga, L Russo
Nov 5, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M MandalaS Marsoni
Nov 22, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A MaraveyasG Bozas
Feb 18, 2012·The New England Journal of Medicine·Giancarlo AgnelliUNKNOWN SAVE-ONCO Investigators
Jul 28, 2012·Thrombosis and Haemostasis·Johannes ThalerIngrid Pabinger
Sep 26, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonas AhlbrechtIngrid Pabinger
Feb 13, 2013·European Journal of Clinical Investigation·Johannes ThalerIngrid Pabinger
May 15, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanUNKNOWN American Society of Clinical Oncology Clinical Practice
Aug 3, 2013·Blood·Ingrid PabingerCihan Ay

❮ Previous
Next ❯

Citations

Nov 8, 2017·European Journal of Haematology·Yusrah Harahsheh, Kwok M Ho
Oct 20, 2017·Interactive Cardiovascular and Thoracic Surgery·Thomas Decker ChristensenAnne-Mette Hvas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Related Papers

Journal of the National Comprehensive Cancer Network : JNCCN
Alok A Khorana
Critical Reviews in Oncology/hematology
Diana L HannaTed Wun
© 2022 Meta ULC. All rights reserved